285 related articles for article (PubMed ID: 35355983)
1. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.
Guo Y; Yang J; Ren K; Tian X; Gao H; Tian X; Zhang X; Kan Q
Front Immunol; 2022; 13():861525. PubMed ID: 35355983
[TBL] [Abstract][Full Text] [Related]
2. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
3. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.
Xu Q; Chen S; Hu Y; Huang W
Front Immunol; 2021; 12():711433. PubMed ID: 34512634
[TBL] [Abstract][Full Text] [Related]
4. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.
Chen L; Zhou Q; Liu J; Zhang W
Front Immunol; 2021; 12():759565. PubMed ID: 34777372
[TBL] [Abstract][Full Text] [Related]
5. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
6. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma.
Xie F; Bai Y; Yang X; Long J; Mao J; Lin J; Wang D; Song Y; Xun Z; Huang H; Yang X; Zhang L; Mao Y; Sang X; Zhao H
Int Immunopharmacol; 2020 Dec; 89(Pt A):107135. PubMed ID: 33189609
[TBL] [Abstract][Full Text] [Related]
8. Immune cell infiltration and immunotherapy in hepatocellular carcinoma.
Jiang Y; Lin L; Lv H; Zhang H; Jiang L; Ma F; Wang Q; Ma X; Yu S
Math Biosci Eng; 2022 May; 19(7):7178-7200. PubMed ID: 35730302
[TBL] [Abstract][Full Text] [Related]
9. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
10. Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy.
Yang S; Cheng Y; Wang X; Wei P; Wang H; Tan S
Front Genet; 2021; 12():777931. PubMed ID: 34899862
[No Abstract] [Full Text] [Related]
11. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
12. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma.
Gao B; Wang Y; Lu S
Sci Rep; 2023 Jan; 13(1):1137. PubMed ID: 36670201
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy.
Zhang X; Shi M; Chen T; Zhang B
Mol Ther Nucleic Acids; 2020 Dec; 22():298-309. PubMed ID: 33230435
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration.
Chen C; Tang D; Gu C; Wang B; Yao Y; Wang R; Zhang H; Gao W
Dis Markers; 2022; 2022():2361507. PubMed ID: 36411824
[TBL] [Abstract][Full Text] [Related]
15. Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer.
Wu W; Wang X; Le W; Lu C; Li H; Zhu Y; Chen X; An W; Xu C; Wu Q; Wang L
Front Immunol; 2022; 13():1001297. PubMed ID: 36700224
[TBL] [Abstract][Full Text] [Related]
16. The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.
Du M; Qu Y; Qin L; Zheng J; Sun W
J Cell Mol Med; 2024 Apr; 28(7):e18168. PubMed ID: 38494848
[TBL] [Abstract][Full Text] [Related]
17. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
18. A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma.
Xiao J; Liu T; Liu Z; Xiao C; Du J; Zuo S; Li H; Gu H
Cells; 2022 Jul; 11(15):. PubMed ID: 35892599
[TBL] [Abstract][Full Text] [Related]
19. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression.
Xiao X; Mo H; Tu K
Int Immunopharmacol; 2020 Dec; 89(Pt A):107043. PubMed ID: 33039961
[TBL] [Abstract][Full Text] [Related]
20. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Hong T; Su W; Pan Y; Tian C; Lei G
Front Immunol; 2022; 13():951459. PubMed ID: 36189258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
